Icagen Inc

Icagen — Taglich Conference 2016

14 slides from Icagen's conference presentation, May 3, 2016

  1. Slide 1: Advancing Ion Channel & Transporter Discovery

    CAGEN ADVANCING ION CHANNEL & TRANSPORTER DISCOVERY Taglich Conference May 3, 2016 (©2015 ICAGEN

  2. Slide 2: Advancing Ion Channel & Transporter Discovery

    ™ ADVANCING ION CHANNEL & TRANSPORTER DISCOVERY As a leading drug discovery services company, Icagen brings a unique approach and deep experience in the ion channel field, now enhanced by the XRpro® platform, to offer industry-leading novel drug discovery and biomarker development capabilities to ph

  3. Slide 3: Forward Looking Statement

    Forward Looking Statement ICAGEN Lee Certain statements in this presentation relating to Icagen, Inc. (“icagen ’) contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking Statements are

  4. Slide 4: Leadership Team

    Leadership Team ICAGEN Tim Tyson Chairman of the Board 35+ yrs biopharma leadership BMS, GSK, Valeant, Aptuit (©2015 ICAGEN Richie Cunningham President & CEO 20+ yrs healthcare industry leadership Premier Inc., Valeant, Boehringer- Ingelheim Doug Krafte Chief Scientific Officer 25+ yrs biotech & pha

  5. Slide 5: Pharmaceutical Services Outsourcing Market

    Pharmaceutical Services Outsourcing Market ICAGEN Lee Outsourcing * Well documented patent Outsourcing Segments cliff challenges for Pharmaceutical Companies * Pharmaceutical Companies are ina state of restructuring and transition —_ Discovery > + Development » + Commercialization > * The trends for

  6. Slide 6: Our Space - Drug Discovery Segment

    Our Space - Drug Discovery Segment ICAGEN Lee Outsourcing Drug Discovery Drug Discovery Outsourcing as a Macro Trend — Market Overview * Greater comfort to outsource drug Annual Growth Rate Of 13.3% between discovery is growing 2014 and 2019 29.7 27.4 * Move from fixed to 21.8 variable cost model ch

  7. Slide 7: Opportunistic Acquisition: History & Evolution

    Opportunistic Acquisition ICAGEN (©2015 ICAGEN History & Evolution Biotech Heritage Developing Molecules to take into the clinic @, 1992 dey 1999 DB) 2007 (Pfizer) 2017 pesos leagen enters intodug ase completes esp ine toned Fiat icagenlonchanel,—igcoverycalboraton with acuistonofleagen and te ascov

  8. Slide 8: Opportunistic Acquisition

    Opportunistic Acquisition ICAGEN Lee XRprosciences » ICAGEN July 2015 lon Channel/ Transporter Contract Research Organization Combining 20 years of expertise along with unique technology capabilities ICAGEN This capability will enable us to understand the full potential of XRpro® while capitalizing

  9. Slide 9: Our Business

    Our Business ICAGEN as me S o= ESB =D SS DEDsE» Early Stage of Drug Discovery Multiple therapeutic opportunities CNS , CardioPulmonary CardioMetabolic Cell line development Assay development Oncology = Immunology A Data Generation (©2015 ICAGEN

  10. Slide 10: Commercial Update

    Commercial Update ICAGEN eee 7 Purchase Orders 4800000 Large Pharma Clients 4420000 s.0m000 4 200000 J | seoomn0 Biotech Clients 0000 200000 s a a 3 as 2 Government Grants Number of Programs 16 On-going Programs 1 4.7 7 Million in PO’s (2016) 2 | - a Jan Feb Mar : (©2015 ICAGEN 40

  11. Slide 11: Projections

    Projections ICAGEN ——————— 3 Year Projection $60,000,000 Revenue 12-50M $50,000,000 $40,000,000 $30,000,000 $20,000,000 $10,000,000 S$. 2014 2015 2016 2017 2018 2016 Projections $6-11M (©2015 ICAGEN oT

  12. Slide 12: Private Placement Update & Trading

    Private Placement Update & Trading ICAGEN Lee * In December 2015 Gross proceeds - $8.855 million and net proceeds - $8,109 million were raised — 1.265 million units at $7.00 per unit, (four common shares and one five year warrant for common share exercisable at $1.75) through Taglich Brothers — A to

  13. Slide 13: Summary

    Summary ICAGEN eEEEE——————eeeee * Recognized leader in lon Channel Market « Market is strong and growing * Outsourcing is increasing faster than market growth * Expecting cash flow breakeven to occur in 2016 * Expect continued company growth based on these dynamics Actively looking at additional syn

  14. Slide 14: Questions

    CAGEN ADVANCING ION CHANNEL & TRANSPORTER DISCOVERY Questions (©2015 ICAGEN

Icagen — Taglich Conference 2016 on 6ix